
News|Articles|July 7, 2026
Q2 2026 Recap: Hepatology News & Updates
Author(s)Abigail Brooks, MA
Fact checked by: Victoria Johnson
Catch up on Q2 hepatology headlines, including the historic FDA approval of bulevirtide for hepatitis delta, new data on bepirovirsen for HBV, and more.
Advertisement
Advertisement
The second quarter of 2026 marked a pivotal period in
Related to this article

Jasmohan Bajaj, MD, MS, joins Nancy Reau, MD, and Kimberly Brown, MD, on who to screen for HE in clinic and how to prepare patients and families.

Stay updated with the latest healthcare breakthroughs, including 96-week durability data for GSK’s bepirovirsen in hepatitis B, and more.

Children receiving 50 nmol PVX108 increased their tolerated peanut dose 2.4-fold, with no treatment-related anaphylaxis in the phase 2 trial.

Ackerman and Bunick review 52-week AMETHYST data for litifilimab in refractory cutaneous lupus and make the case for dermatology-led CLE care.

Lawrence Eichenfield, MD, discusses phase 2 nemolizumab data in children aged 2 - 11 with atopic dermatitis, from caregiver-rated itch to sleep gains.

In this Q&A, Jennifer K. Priessnitz, MD, explains why FAERS reporting proportions should not drive biologic selection and what data are needed next.

At ACAAI 2026, Jennifer Priessnitz, MD presented data which found omalizumab had the highest anaphylaxis reporting proportion among 7 respiratory biologics.
Advertisement
Advertisement

